Assembly Biosciences annual operating margin
2017
2018
2019
2020
2021
2023
2024
2025
Assembly Biosciences's operating margin was −16.76% for fiscal 2025.
View full Assembly Biosciences company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −16.76% | +142.50 pp |
| 2024 | 2024-12-31 | −159.26% | +743.24 pp |
| 2023 | 2023-12-31 | −902.50% | +1219.15 pp |
| 2021 | 2021-12-31 | −2,121.65% | −2039.76 pp |
| 2020 | 2020-12-31 | −81.89% | +561.56 pp |
| 2019 | 2019-12-31 | −643.44% | −17.03 pp |
| 2018 | 2018-12-31 | −626.42% | −47.34 pp |
| 2017 | 2017-12-31 | −579.08% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −47.44% | +67.80 pp |
| Q1 2026 | 2026-03-31 | −138.44% | −32.90 pp |
| Q4 2025 | 2025-12-31 | 46.62% | +203.37 pp |
| Q3 2025 | 2025-09-30 | −100.87% | +59.19 pp |
| Q2 2025 | 2025-06-30 | −115.24% | +27.77 pp |
| Q1 2025 | 2025-03-31 | −105.54% | +79.92 pp |
| Q4 2024 | 2024-12-31 | −156.75% | +18.47 pp |
| Q3 2024 | 2024-09-30 | −160.06% | +141.75 pp |
| Q2 2024 | 2024-06-30 | −143.01% | +3679.75 pp |
| Q1 2024 | 2024-03-31 | −185.46% | −173.85 pp |
| Q4 2023 | 2023-12-31 | −175.22% | −191.93 pp |
| Q3 2021 | 2021-09-30 | −301.81% | +376.80 pp |
| Q4 2020 | 2020-12-31 | −3,822.76% | −3221.04 pp |
| Q3 2020 | 2020-09-30 | −11.61% | +602.73 pp |
| Q2 2020 | 2020-06-30 | 16.71% | +656.32 pp |
| Q1 2020 | 2020-03-31 | −678.61% | +50.76 pp |
| Q4 2019 | 2019-12-31 | −601.72% | +103.02 pp |
| Q3 2019 | 2019-09-30 | −614.35% | −87.63 pp |
| Q2 2019 | 2019-06-30 | −639.61% | +204.58 pp |
| Q1 2019 | 2019-03-31 | −729.37% | −261.71 pp |
| Q4 2018 | 2018-12-31 | −704.74% | −236.62 pp |
| Q3 2018 | 2018-09-30 | −526.71% | +48.34 pp |
| Q2 2018 | 2018-06-30 | −844.19% | — |
| Q1 2018 | 2018-03-31 | −467.66% | — |
| Q3 2017 | 2017-09-30 | −468.12% | — |
| Q2 2017 | 2017-06-30 | −575.05% | — |
Over the last five reported fiscal years, Assembly Biosciences's operating margin increased from −643.44% to −16.76%, a change of +626.68 percentage points. The latest reported quarter, Q2 2026, shows −47.44%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Assembly Biosciences filings at SEC.gov ↗